Meeting
2023 ASCO Annual Meeting
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Authors
Sylvie Lorenzen
Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, München, Germany
Sylvie Lorenzen , Thorsten Oliver Goetze , Peter C. Thuss-Patience , Jorge Riera-Knorrenschild , Eray Goekkurt , Tobias Nicolaas Dechow , Thomas Jens Ettrich , Ralf Dieter Hofheinz , Kim Barbara Luley , Daniel Pink , Udo Lindig , Gunnar Folprecht , Gunter Schuch , Michael Bitzer , Volker Heinemann , Stefan Angermeier , Claus Bolling , Sabine Junge , Claudia Pauligk , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03647969
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4050)
DOI
10.1200/JCO.2023.41.16_suppl.4050
Abstract #
4050
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
First Author: Salah-Eddin Al-Batran
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
First Author: Lin Shen
Poster
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
First Author: Yelena Y. Janjigian